A multi centre, double-blind, double-dummy, placebo-controlled, randomised, adaptive, dose-range study to evaluate the safety and efficacy of SB-773812 administered once daily for 12 weeks in adults with schizophrenia.

Trial Profile

A multi centre, double-blind, double-dummy, placebo-controlled, randomised, adaptive, dose-range study to evaluate the safety and efficacy of SB-773812 administered once daily for 12 weeks in adults with schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs SB 773812 (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jul 2011 New source added and integrated (European Clinical Trials Database, EudraCT2005-002883-27).
    • 26 Jun 2007 Status changed from recruiting to completed.
    • 20 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top